By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ProMetic BioSciences, Inc. 

R&D and Clinical Trials
500 Cartier West Boulevard, Suite 150
Laval  Quebec  H7V 5B7  Canada
Phone: 450-781-1394 Fax: 450-781-1403




Company News
FDA Confirms ProMetic BioSciences, Inc.'s PBI-4050 IPF Clinical Trial Design 4/18/2017 7:45:33 AM
ProMetic BioSciences, Inc. And Shenzhen Royal Asset Management (SRAM) To Establish A Joint Venture To Develop, Manufacture And Commercialize PBI-4050, PBI-4547 AND PBI-4425 In China 3/30/2017 6:51:36 AM
Positive Response In Kidney And Urinary Tract To ProMetic BioSciences, Inc.'s Plasminogen Treatment In A Plasminogen Deficient Patient Under An Expanded Access (Compassionate Use) Protocol In The USA 5/11/2016 6:16:14 AM
ProMetic BioSciences, Inc. Secures $30 Million Follow-On Financing From Structured Alpha LP, An Affiliate Of Thomvest Asset Management Inc. 3/3/2016 6:22:39 AM
ProMetic BioSciences, Inc. Confirms PBI-4050's Efficacy In Patients Suffering From Type 2 Diabetes And Metabolic Syndrome 12/1/2015 6:42:42 AM
ProMetic BioSciences, Inc.'s Plasminogen Drug Successfully Used To Treat Plasminogen Deficient Infant In Critical Condition 11/4/2015 6:54:58 AM
Octapharma AG Provides ProMetic BioSciences, Inc. With a $4.5 M Advance on a Long-Term Supply Agreement 10/1/2009 10:54:59 AM
ProMetic BioSciences, Inc. Signs Long-Term Supply Agreement With Major Global Pharmaceutical Company and Secures $8.9 M Initial Order for Mimetic Ligand(TM) Product 9/24/2009 11:27:37 AM
Sumitomo Pharmaceuticals Co. Ltd. to Act as Advisor to ProMetic BioSciences, Inc. for Japanese Market 5/1/2009 9:42:27 AM
HemCon Medical Technologies, Inc. And ProMetic BioSciences, Inc. Announce Collaborative Development Agreement 3/3/2009 9:22:07 AM